Biologic drugs generate more revenue per product than any other class of medicine. They also carry more patents, attract more […]

The Hatch-Waxman Act created the modern generic drug industry in 1984. Forty years later, the Paragraph IV certification it established

The Patent Trial and Appeal Board has quietly become the most consequential forum in pharmaceutical IP. This is the definitive

Every year, pharmaceutical companies collectively forfeit billions in potential patent term by misusing one of the most misunderstood tools in

Two off-patent molecules. A single tablet. A decade of exclusivity and margins that rival any branded biologic. That is the

The active pharmaceutical ingredient gets all the attention. Patent cliffs, IND filings, NDA approvals, blockbuster valuations — the API is

Every excipient supplier tracks global market size. Few track which drugs they are actually inside. That gap between macro estimates

How the five judges who control half of all ANDA litigation are reshaping patent strategy, generic timelines, and drug revenue

Between 2025 and 2030, roughly $400 billion in annual pharmaceutical revenue becomes legally contestable. That figure is not a projection